Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that it has signed its first Contribution Agreement with the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP).

This research funding will be used to study genomic correlations in severe sepsis patients. Specifically, the contribution will go towards the continued development of Sirius’ pharmacogenomic diagnostic intended to assess responsiveness to recombinant human activated Protein C (developed and marketed by Eli Lilly and Company under the trademark Xigris® in patients with severe sepsis at high risk of death.

Dr Brad Popovich, President and CEO of Sirius Genomics, comments, "This financial support demonstrates the willingness of the Canadian government to sustain innovation in critical areas of growth such as genomics and personalized medicine. The program provides an important service for small, rapidly growing Canadian companies such as ours."

Source: Sirius Genomics